Back to Quality Research
GMEDGlobus Medical
Health Care · Medical/Dental Instruments · Large
$81.41−0.31%
As of 23 Oct 2026Mkt cap $10.8B
Stage 13
WATCH
Fundamentals
52.7/75
Technical
10.0/15
Independent
62.7/90
GCAE viewbusiness is credible but technical recovery is not yet actionable
Price
- 1M
- +9.6%
- 3M
- +4.0%
- 6M
- −14.2%
- 1Y
- +30.6%
Financials & valuation
Cached filing evidence · as of 2026-10-02
Valuation
- P/E
- 20.8xHist median 38.7x
- Forward P/E
- —No validated forward-estimate source
- Price / FCF
- 14.8x
- FCF yield
- 6.8%
Quality
- ROIC
- 11.1%
- Operating margin
- 8.5%
- FCF margin
- 20.0%
- Current ratio
- 4.3x
Growth
- Revenue growth
- +16.7%Latest FY YoY
- Revenue CAGR
- +32.3%
- EPS CAGR
- +28.4%
- FCF CAGR
- +28.0%
Capital
- Share-count trend
- +9.3%3Y annualised
- Net cash
- $408M-0.5x OCF
Annual trend
- CAGR 2021–2025
- +32.3%
- Latest · 2025
- $3B
- YoY
- +16.7%
GCAE Research
- Quality Research
- PRE-AI
- Acceleration Radar
- FUNDAMENTAL GATE FAIL
- THE ONE
- NOT FLAGGED
- Final / Opportunity
- NOT FLAGGED
Key takeaway
business is credible but technical recovery is not yet actionable
Unresolved question
No reliable unresolved question is available from the current committed evidence.
Watch next
- Next earnings · 2026-11-05
More details & evidence
Production decision
- Stage 13
- WATCH
- Technical state
- approaching-support
- Rotation
- tailwind
- Evidence
- fresh
Presentation freshness
- Stage 11 market
- 2026-10-23 · Massive
- Financial cache
- 2026-10-02
- Quality Research
- CURRENT
- THE ONE
- NOT FLAGGED
Authority
- Company page
- Presentation only
- Scores
- Frozen GCAE production outputs
- Research
- Research-only lanes; no score override
- Private portfolio
- Not loaded